That's the title of a Wall Street Journal report by Timothy W. Martin. It's subtitled, "Tighter Rules on Compounders Slow to Emerge Even as 24 Die From Disease This Year."
Nearly a year after a nationwide outbreak of fungal meningitis erupted, new cases of the disease are still emerging, and efforts to tighten regulation of the type of pharmacy behind the outbreak are moving slowly.
The Food and Drug Administration has reported 14 multistate or national voluntary recalls so far this year of products made by so-called compounding pharmacies, which custom-mix large batches of medications not available from pharmaceutical companies. The FDA reported only two recalls of products from such pharmacies in 2012, including the recall of the injection behind the fungal-meningitis cases. There were none in the four years before that.
The medicines recalled this year by their makers include cataract drops, testosterone pellets and an injection like the one behind the meningitis outbreak.
A Senate bill that would give the FDA oversight of many large compounding pharmacies—which operate like manufacturers and sell drugs all over the country—is one of only a few pieces of legislation that may make it to the Senate floor this fall, according to Senate Democratic aides. Even if successful, it would be months, if not years, before enforcement took effect.
The article has additional details on the Senate legislation. Earlier coverage of compounding pharmacies is at the link.
The Georgia Department of Corrections recently used a compounding pharmacy to produce a batch of lethal injection drugs. Other departments of corrections are considering using such facilities. Related posts are in the lethal injection index.